Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model

Cancer Gene Therapy

Volumn 4, Issue 2, 1997, Pages 105-112

  Shevelev, Alexander ^a,c   Burfeind, Peter ^a   Schulze, Ekkehard ^a   Rininsland, Frauke ^a   Johnson, Thomas R ^a   Trojan, Jerzy ^a,d   Chernicky, Cheryl L ^a   Hélène, Claude ^b   Ilan, Judith ^a   Ilan, Joseph ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^d HÔPITAL PAUL BROUSSE   (France)

Author keywords

C6 cells; Cell transfection; MHC I; Nexin I

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CARRIER PROTEIN; CELL SURFACE RECEPTOR; HLA ANTIGEN CLASS 1; OLIGONUCLEOTIDE; PROTEASE NEXINS; SOMATOMEDIN C;

ANIMAL; ARTICLE; CELL CULTURE; CHEMISTRY; CONFORMATION; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; GLIOBLASTOMA; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; PATHOLOGY; PLASMID; PROTEIN SYNTHESIS; RAT; UPREGULATION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLIOBLASTOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; PLASMIDS; PROTEIN BIOSYNTHESIS; RATS; RECEPTORS, CELL SURFACE; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0031084896     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Humbel RE. Insulin-like growth factors I and II. Eur J Biochem. 1990;190:445-462.
2. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulinlike growth factors and cancer. Ann Intern Med. 1995;122: 54-59.
3. Johnson TR, Blossey BK, Rudin SD, Ilan J. Regulation of IGF-I RNA transcript levels in C6 glial cells J Cell Biol. 1991;111:505 (abstr.).
4. Kiess W, Lee L, Grayham DE, et al. Rat C6 glial cells synthesize insulin-like growth factor I (IGF-I) and express IGF-I receptors and IGF-II/mannose-6-phosphate receptors. Endocrinology. 1989;124:1727-1736.
5. Trojan J, Johnson TR, Rudin SD, Ilan Ju, Tykocinski ML, Ilan Jo. Treatment and prevention of rat glioblastoma by C6 cells expressing antisense IGF-I RNA. Science. 1993; 259:94-97.
6. Hélène, C. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonueleotides. Eur J Cancer. 1991:27:1466-1471.
7. Maher LJ III, Wold B, Dervan PB. Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation. Science. 1989;245:725-730.
8. Francois J-C, Saison-Behmoaras T, Thuong NT, Hélène C. Inhibition of restriction endonuclease cleavage via triple helix formation by homopyridine oligonucleotides. Biochemistry. 1989;28:9617-9619.
9. Postel EH, Flint SJ, Kessler DJ, Hogan ME. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci USA. 1991;88:8227-8231.
10. McShan WM, Rossen RD, Laughter AH, et al. Inhibition of transcription of HIV-I in infected human cells by oligodeoxynucleotides designed to form DNA triple helices. Chemotherapy. 1992;267:5712-5721.
11. Mayfield C, Ebbinghaus S, Gee J, et al. Triplex formation by the human Ha-ras promoter inhibits Sp 1 binding and in vitro transcription. J Biol Chem. 1994;269:18232-18238.
12. Grigoriev M, Praseuth D, Guieysse AL, et al. Inhibition of gene expression by triple helix-directed DNA cross-linking at specific sites. Proc Nail Acad Sci USA. 1993;90:3501-3505.
13. Grigoriev M, Praseuth D, Robin P, et al. A triple helixforming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NF Kappa B binding to interleukin-2 receptor alpha-regulatory sequence. J Biol Chem. 1992;267:3389-3395.
14. Mayfield C, Squibb M, Miller D. Inhibition of nuclear protein binding to the human Ki-ras promoter by triplexforming oligonucleotides. Biochemistry. 1994;33:3358-3363.
15. Roy C. Triple-helix formation interferes with the transcription and hinged DNA structure of the interferon-inducible 6-16 promoter. Eur J Biochem. 1994;220:493-503.
16. Hélène C. The antigene strategy: control of gene expression by triplex-forming-oligonucleotides. Anticancer Drug Des. 1991;6:569-584.
17. Kim S-W, Lajara R, Rotwein P. Structure and function of a human insulin-like growth factor-1 gene promoter. Mol Endocrinol. 1991;5:1964-1972.
18. Trojan J, Johnson TR, Rudin SD, et al. Gene therapy of murine teratocarcinoma: separate functions for insulinlike growth factors I and II in immunogenicity and differentiation. Proc Natl Acad Sci USA. 1994;91:6088-6092.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
20. Murphy LJ, Bell GI, Duckworth ML, Friesen HG. Identification, characterization and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. Endocrinology. 1987;121:684-691.
21. Cleveland DW, Lopata MA, MacDonald RJ, et al. Number and evolutionary conservation of α- and β-tubulin and cytoplasmic β- and γ-actin genes using specific cloned cDNA probes. Cell. 1980;20:95-105.
22. Benda P, Lightbody J, Sato G, Levine L, Sweet W. Differential rat glial cell strain in tissue culture. Science. 1969;161:370-371.
23. Chomczynsky P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocianate-phenol-chloro-form extraction. Anal Biochem. 1987;162:156-159.
24. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 1992;257:967-971.
25. Escudé C, Francois JC, Sun JS, et al. Stability of triple helices containing RNA and DNA strands: experimental and molecular modeling studies. Nucleic Acids Res. 1993: 21:5547-5553.
26. Ing NH, Beekman JM, Kessler DJ, et al. In vivo transcription of a progesterone-responsive gene is specifically inhibited by a triplex-forming oligonucleotide. Nucleic Acids Res. 1993;1:2789-2796.
27. Scaggiante B, Morassutti C, Tolazzi G, et al. Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells. FEBS Lett. 1994;352:382-384.
28. Degols G, Clarence J-P, Lebléu B, Léonetti J-P. Reversible inhibition of gene expression by psoralen functionalized triple helix forming oligonucleotide in intact cells. J Biol Cliem. 1994;269:16933-16937.
29. Montarras D, Pinset C, Pérez M-C, Ilan J, Gros F. Muscle differentiation: insulin-like growth factors as positive modulators of myogenic regulatory genes? C R Acad Sci Paris, Life Sciences. 1993;316:1029-1031.
30. Trojan J, Blossey BK, Johnson TR, et al. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA. 1992;89:4874-4878.
31. Macaulay VM, Bates PJ, McLean MJ, et al. Inhibition of aromatase expression by a psoralen-linked triplex-forming oligonucleotide targeted to a coding sequence. FEBS Lett. 1995;372:222-228.
32. Porumb H, Gousset H, Letellier R, et al. Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide. Cancer Res. 1996;56:515-522.
33. Elliot BE, Carlow DA, Rodricks A-M, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res. 1989;53:181-245.
34. Hämmerling GJ, Klar D, Puľm W, Momburg F, Moldenhauer G. The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim Biophys Acta. 1987;907:245-259.
35. Goepel JR, Rees RC, Rogers K, Stoddard CJ, Thomas WEG, Shepherd L. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer. 1991;64:880-883.
36. Saji M, Moriarty J, Ban T, Singer DS, Kohn LD. Major histocompatibility complex class I gene expression in rat thyroid cells is regulated by hormones, methimazole and iodide as well as interferon. J Clin Endocrinol Metab. 1992;75:871-878.
37. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman, M. Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985;315:301-305.
38. Trojan J, Due HT, Upegui-Gonzalez LC, et al. Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett. 1996; 212:9-12.
39. Reinhard E, Suidan HS, Pavlik A, Monard D. Glia-derived nexin/protease nexin-1 is expressed by a subset of neurons in the rat brain. J Neurosci Res. 1994;37:256-270.
40. Murphy PG, Lenz SP, Dobson M, Arndt AD, Hart DA. Identification, characterization and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. Biochem Cell Biol. 1993;71:248-254.
41. Scott RW, Bergman BL, Bajpai A, et al. Protease nexin. J Biol Chem. 1985;260:7029-7034.
42. Danø K, Andreasen A, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
43. Bergman BL, Scott RW, Bajpai A, Watts S, Baker JB. Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci USA. 1986;83:996-1000.
44. Guttridge DC, Lau AL, Cunningham DD. Protease nexin-1, a thrombin inhibitor, is regulated by interleukin-1 and dexamethasone in normal human fibroblasts. J Biol Chem. 1993;268:18966-18974.
45. Bleuel A, de Gasparo M, Whitebread S, Puttner I, Monard D. Regulation of protease nexin-1 expression in cultured Schwann cells is mediated by angiotensin II receptors. J Neurosci. 1995;15:750-761.
46. Zou Z, Anisowicz A, Hendrix MJC, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 1994;263:526-529.
47. Resnicoff M, Abraham D, Yutanawiboonchai W, et al. The insulin-like growth factor I receptor protects cells from apoptosis in vivo. Cancer Res. 1995;56:2463-2469.
48. Taghian A, Bucach W, Zietman A, Freeman J, Gioioso D, Smit, HD. Quantitative comparison between the transplantability of human and murine tumors into the brain of NCr/Sed-nu/nu Nude and severe combined immunodeficient mice. Cancer Res. 1993;53:5018-5021.
49. Beal PA, Dervan PB. Second structural motif for recognition of DNA by oligonucleotide-directed triple helix formation. Science. 1991;251:1360-1363.
50. Skoog JU, Maher LJ III. Repression of bacteriophage promoters by DNA and RNA oligonucleotides. Nucleic Acids Res. 1993;21:2131-2138.
51. Hollingsworth MA, Closken C, Harris A, McDonald CD, Pahwa GS, Maher LJ III. A nuclear factor that binds purine-rich, single-stranded oligonucleotides derived from Si-sensitive elements upstream of the CFTR gene and the MUC 1 gene. Nucleic Acids Res. 1994;22:1138-1146.
52. Semerad CL, Maher LJ III. Exclusion of RNA strands from a purine motif triple helix. Nucleic Acids Res. 1994; 22:5321-5325.
53. Kiyama R, Camerini-Otero RD. A triplex DNA-binding protein from human cells: purification and characterization. Proc Natl Acad Sci USA. 1991;88:10450-10454.